年龄校正的查尔森合并症指数作为接受放化疗的下咽癌的预后因素。
Age-adjusted Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiation therapy.
作者信息
Tanaka Hidenori, Takenaka Yukinori, Nakahara Susumu, Hanamoto Atshushi, Fukusumi Takahito, Michiba Takahiro, Takemoto Norihiko, Cho Hironori, Yamamoto Masashi, Yamamoto Yoshifumi, Inohara Hidenori
机构信息
a Department of Otorhinolaryngology-Head and Neck Surgery , Osaka University Graduate School of Medicine , Suita , Japan.
出版信息
Acta Otolaryngol. 2017 Jun;137(6):668-673. doi: 10.1080/00016489.2016.1269946. Epub 2017 Jan 13.
CONCLUSION
The age-adjusted Charlson comorbidity index (ACCI) was associated with overall survival, disease-specific survival, and non-cancer death in patients treated with chemoradiation therapy (CRT) for hypopharyngeal cancer (HPC). Further studies using other CRT regimens are required.
OBJECTIVE
To investigate the impact of the ACCI on survival in patients with HPC.
METHODS
This study reviewed 128 patients with HPC who received CRT between 2004-2012. The survival rates and the cumulative incidence of non-cancer death according to the ACCI were estimated. A Cox proportional hazard model was used to assess the hazard ratio (HR) of the ACCI.
RESULTS
The disease-specific survival rates at 3 years for the low ACCI group, moderate group, and high group were 80.1%, 45.8%, and 54.8%, respectively (p = 0.007). The laryngectomy-free survival rates at 3 years were 61%, 39.7%, and 37.1%, respectively (p = 0.137). The cumulative incidences of non-HPC death were 5% for the low/moderate ACCI group and 15.5% for the high ACCI group (p = 0.031). The HRs compared to the low ACCI group for overall survival, disease-specific survival, and laryngectomy-free survival were 2.61 and 2.74, 2.55 and 2.27, and 1.75 and 1.97 in the moderate and high ACCI groups, respectively.
结论
年龄校正后的查尔森合并症指数（ACCI）与接受放化疗（CRT）治疗的下咽癌（HPC）患者的总生存期、疾病特异性生存期和非癌症死亡相关。需要使用其他CRT方案进行进一步研究。
目的
探讨ACCI对HPC患者生存的影响。
方法
本研究回顾了2004年至2012年间接受CRT治疗的128例HPC患者。根据ACCI估计生存率和非癌症死亡的累积发生率。采用Cox比例风险模型评估ACCI的风险比（HR）。
结果
低ACCI组、中度组和高度组3年的疾病特异性生存率分别为80.1%、45.8%和54.8%（p = 0.007）。3年的无喉切除术生存率分别为61%、39.7%和37.1%（p = 0.137）。低/中度ACCI组非HPC死亡的累积发生率为5%，高ACCI组为15.5%（p = 0.031）。与低ACCI组相比，中度和高度ACCI组的总生存期、疾病特异性生存期和无喉切除术生存期的HR分别为2.61和2.74、2.55和2.27、1.75和1.97。
Zotero 插件